Form 4: LENZ Therapeutics Director Receives Stock Option Grant
Director Compensation Disclosure
Director Zachary Scheiner was granted 22,100 stock options in LENZ Therapeutics, which he holds for the benefit of RA Capital Management.
Summary
- Director Zachary Scheiner received a grant of 22,100 stock options on June 15, 2026.
- The options have an exercise price of $6.63 per share.
- The options are set to vest fully on the earlier of June 15, 2027, or the date of the next annual stockholders meeting.
- The reporting person disclaims beneficial ownership, as the options are held for the benefit of RA Capital Management funds.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified; this is a standard compensatory grant for a director.
Risks
- Vesting is contingent upon the reporting person remaining an Outside Director through the vesting date.
Future Outlook
The options vest in full on June 15, 2027, or the next annual meeting, provided the director remains in their role.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board members are incentivized to oversee long-term corporate strategy and value creation.
Comparison to Industry Standards
- The grant size and vesting schedule are consistent with standard director compensation policies for small-cap biotechnology firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of stock options under the Outside Director Compensation Policy. | 06/15/2026 | Standard alignment of director incentives. |
Related Party Transactions
- The reporting person holds the options for the benefit of RA Capital Management, L.P. and associated funds, and is obligated to turn over net proceeds to the Adviser.
Stakeholder Impact
- Minimal impact on shareholders; represents standard director equity compensation.
Next Steps
- Vesting of options on June 15, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 06/15/2026 | Transaction date of the stock option grant. |
| 06/15/2027 | Vesting date for the stock options. |
| 06/15/2036 | Expiration date of the stock options. |
Keywords
LENZ Therapeutics, LENZ, Director Compensation, Stock Options, Form 4, Insider Trading, RA Capital Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.